Protein kinase C inhibitors as novel anticancer drugs

Expert Opinion on Investigational Drugs

Volumn 10, Issue 12, 2001, Pages 2117-2140

  Goekjian, P G ^a   Jirousek, M R ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

Cancer; Cancer therapeutics; Cell cycle; Isozymes; New targets cancer therapeutics; Oncology; PKC; PKC inhibitor; Signal transduction

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 3 [8 [(DIMETHYLAMINO)METHYL] 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL] 4 (1 METHYL 1H INDOL 3 YL) 1H PYRROLE 2,5 DIONE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; BRYOSTATIN 1; CAMPTOTHECIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; DRUG METABOLITE; ENZASTAURIN; FLUOROURACIL; GEMCITABINE; ILMOFOSINE; ISIS 3521; ISOPROTEIN; LY 379196; MIDOSTAURIN; MITOMYCIN C; PACLITAXEL; PERIFOSINE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; AREA UNDER THE CURVE; BREAST CANCER; CANCER; CANCER THERAPY; CELL CYCLE; CELL DIFFERENTIATION; CELL INVASION; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TRANSPORT; HUMAN; HUMAN CELL; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OUTCOMES RESEARCH; REGULATORY MECHANISM; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTEIN KINASE C; SUBSTRATE SPECIFICITY;

EID: 0035657643     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.12.2117     Document Type: Review

References (204)

1. Protein Kinase C
2. The extended protein kinase C superfamily
3. Protein kinase C in the treatment of disease: Signal transduction pathways, inhibitors, and agents in development
4. Cell cycle dysregulation and the molecular mechanisms of prostate cancer
5. Differentiation mechanisms and malignancy
6. Role of telomerase in normal and cancer cells
7. Angiogenesis in cancer and other diseases
8. Biological mechanisms in breast cancer invasiveness: Relevance to preventive interventions
9. Lipids: A key role in multidrug resistance?
10. Elevated protein kinase C-betaII is an early promotive event in colon carcinogenesis
11. Protein kinase C in signal transduction and carcinogenesis
12. Potential for protein kinase C inhibitors in cancer therapy
13. Signal transduction as a therapeutic target
14. Protein kinase C: A worthwhile target for anticancer drugs?
15. The protein kinase ABC's of signal transduction as targets for drug development
16. Protein kinase C targeting in antineoplastic treatment strategies
17. Cyclin-dependent kinase and protein kinase C inhibitors: A novel class of antineoplastic agents in clinical development
18. Modulation of protein kinase C in antitumor treatment
19. Protein kinase C-mediated regulation of the cell cycle
20. Connecting signalling and cell cycle progression in growth factor-stimulated cells
21. The role of protein kinase C in the regulation of cell growth and in signalling to the cell nucleus
22. Protein kinases as mediators of phosphoinositide 3-kinase signalling
23. PI-3 kinase in signal transduction, cell transformation, and as a target for chemoprevention of cancer
24. Protein kinase C: A paradigm for regulation of protein function by two membrane-targeting modules
25. Regulation of protein kinase C zeta by PI 3-kinase and PDK-1
26. Multiple pathways control protein kinase C phosphorylation
27. 0 to S transition
28. Mitogenic signal of epidermal growth factor in chick embryo hepatocytes: Role of PKC-alpha
29. Insulin-activated protein kinase C-beta bypasses Ras and stimulates mitogen-activated protein kinase activity and cell proliferation in muscle cells
30. Selective inhibition of rat mesangial cell proliferation by a synthetic peptide derived from the sequence of the C2 region of PKC-beta
31. The Role of Protein Kinase C in Cellular Proliferation and Cell Cycle Control
32. An antisense of protein kinase C-zeta inhibits proliferation of human airway smooth muscle cells
33. Growth hormone and phorbol esters require specific protein kinase C isoforms to activate mitogen-activated protein kinases in 3T3-F442A cells
34. Antisense inhibition of protein kinase C-alpha reverses the transformed phenotype in human lung carcinoma cells
35. In vitro and in vivo suppression of growth of rat liver epithelial tumour cells by antisense oligonucleotide against protein kinase C-alpha
36. AP-1: One switch for many signals
37. Stable transfection of protein kinase C-alpha cDNA in hormone-dependent breast cancer cell lines
38. Advanced glycation end product-induced peroxisome proliferator-activated receptor gamma gene expression in the cultured mesangial cells
39. Activation of protein kinase-C inhibits vitamin D receptor gene expression
40. Serine 157, a retinoic acid receptor alpha residue phosphorylated by protein kinase C in vitro, is involved in RXR. RAR-alpha heterodimerisation and transcriptional activity
41. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts
42. Involvement of p21 (Waf1/Cip1) in protein kinase C-alpha-induced cell cycle progression
43. Regulation of p53 by protein kinase C during multistage carcinogenesis
44. 1 cyclin-dependent kinases
45. Complex regulation of the DNA-binding activity of p53 by phosphorylation: Differential effects of individual phosphorylation sites on the interaction with different binding motifs
46. Multiple biological responses activated by nuclear protein kinase C
47. Phosphatidylglycerol is a physiologic activator of nuclear protein kinase C
48. The role of protein kinase C isoforms in cell proliferation and apoptosis
49. Serine/threonine protein kinases and apoptosis
50. Involvement of protein kinase C-epsilon in glucocorticoid-induced apoptosis in thymocytes
51. Differential Sensitivity of Breast Cancer Cells to Tumour Necrosis Factor-alpha: Involvement of Protein Kinase C
52. Protein kinase C lies on the signalling pathway for vascular endothelial growth factor-mediated tumour development and angiogenesis
53. Overexpression of protein kinase C-beta1 isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells
54. Protein kinase C-alpha is essential for Ramos-BL B cell survival
55. Apoptosis is induced in glioma cells by antisense oligonucleotides to protein kinase C alpha and is enhanced by cycloheximide
56. The involvement of protein kinase C isoenzymes alpha, epsilon and zeta in the sensitivity to antitumour treatment and apoptosis induction
57. Persistent membrane translocation of protein kinase C-alpha during 12-0- tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells
58. Atypical protein kinase C-iota protects human leukaemia cells against drug-induced apoptosis
59. Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis
60. Radiation-induced signal transduction and stress response
61. Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A
62. Ceramide enables Fas to cap and kill
63. PED/PEA-15: An anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis
64. Protein kinase C inhibits CD95 (Fas/APO-1)-mediated apoptosis by at least two different mechanisms in Jurkat T cells
65. Involvement of protein kinase C-beta and ceramide in tumour necrosis factor-alpha-induced but not Fas-induced apoptosis of human myeloid leukaemia cells
66. Protein kinase C-theta cooperates with calcineurin to induce Fas ligand expression during activation-induced T cell death
67. Ceramide does not inhibit protein kinase C beta-dependent phospholipase D activity stimulated by anti-Fas monoclonal antibody in A20 cells
68. Functional dichotomy of protein kinase C (PKC) in tumour necrosis factor-alpha (TNF-alpha) signal transduction in L929 cells. Translocation and inactivation of PKC by TNF-alpha
69. Different roles of protein kinase C alpha and delta isoforms in the regulation of neutral sphingomyelinase activity in HL-60 cells
70. Subtype-specific translocation of the delta subtype of protein kinase C and its activation by tyrosine phosphorylation induced by ceramide in HeLa cells
71. Ceramide-enhanced urokinase-type plasminogen activator (uPA) release is mediated by protein kinase C in cultured microglia
72. N-acylated serinol is a novel ceramide mimic inducing apoptosis in neuroblastoma cells
73. Ceramide directly activates protein kinase C-zeta to regulate a stress-activated protein kinase-signalling complex
74. Ceramide-dependent regulation of p42/p44 mitogen-activated protein kinase and c-Jun N-terminal-directed protein kinase in cultured airway smooth muscle cells
75. p90(RSK) blocks bad mediated cell death via a protein kinase C-dependent pathway
76. The roles of signalling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio-and chemo-sensitisation of tumour cells resulting in the induction of apoptosis and loss of clonogenicity
77. Ribozyme inhibition of the protein kinase C-alpha triggers apoptosis in glioma cells
78. Involvement of protein kinase C-epsilon in thyroid cell death. A truncated chimeric PKC-epsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis
79. Implications of cell death regulation in the pathogenesis and treatment of prostate cancer
80. Critical targets of protein kinase C in differentiation of tumour cells
81. Protein kinase C-(alpha) and -(beta) play antagonistic roles in the differentiation process of THP-1 cells
82. Distinct functions of protein kinase C-alpha and protein kinase C-beta during retinoic acid-induced differentiation of F9 cells
83. Definition by specific antisense oligonucleotides of a role for protein kinase C-alpha in expression of differentiation markers in normal and neoplastic mouse epidermal keratinocytes
84. Protein kinase C isoforms play differential roles in the regulation of adipocyte differentiation
85. Protein kinase C-alpha is an effector of hexamethylene bisacetamide-induced differentiation of Friend erythroleukaemia cells
86. Signaling via vascular endothelial growth factor receptors
87. The proliferative effect of vascular endothelial growth factor requires protein kinase C-alpha and protein kinase C-zeta
88. Characterisation of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
89. Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C-zeta
90. Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells
91. Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase- dependent pathway
92. Eicosanoid activation of extracellular signal-regulated kinase1/2 in human epidermoid carcinoma cells
93. Resistance to antineoplastic treatments: Mechanisms, clinical value
94. Reversal of multidrug resistance by the staurosporine derivatives CGP 41251 and CGP 42700
95. Regulation of volume-activated chloride channels by P-glycoprotein: Phosphorylation has the final say!
96. Mechanism of inhibition of P-glycoprotein-mediated drug transport by protein kinase C blockers
97. Protein kinase C in human renal cell carcinomas: Role in invasion and differential isoenzyme expression
98. Current data on metalloproteinases, obligatory partners of tumour progression
99. Protein kinase C and its isoforms in human breast cancer cells: Relationship to the invasive phenotype
100. The role of protein kinase C-alpha in U-87 glioma invasion
101. TPA-enhanced motility and invasion in a highly metastatic variant (L-10) of human rectal adenocarcinoma cell line RCM-1: Selective role of PKC-alpha and its inhibition by a combination of PDBu-induced PKC and antisense oligonucleotides treatment
102. Adherence to osteopontin via alpha(v)beta3 suppresses phorbol ester-mediated apoptosis in MCF-7 breast cancer cells that overexpress protein kinase C-alpha
103. Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha
104. 2 generation but not degranulation or adherence in differentiated HL60 cells
105. The effect of protein kinase C inhibitors on invasion of human ovary cancer cells
106. Integrins as signalling molecules and targets for tumour therapy
107. Transforming JB6 cells exhibit enhanced integrin-mediated adhesion to osteopontin
108. Adherence of human erythroleukaemia cells inhibits proliferation without inducing differentiation
109. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer
110. 54 human glioblastoma cells
111. Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumour cells
112. Sulfatide binding and activation of leukocytes through an L-selectin-independent pathway
113. Telomerase is controlled by protein kinase C-alpha in human breast cancer cells
114. Telomerase is regulated by protein kinase C-zeta in human nasopharyngeal cancer cells
115. Specificity and mechanism of action of some commonly used protein kinase inhibitors
116. Differential inhibition of cytosolic and membrane-derived protein kinase C activity by staurosporine and other kinase inhibitors
117. Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronised at M phase by nocodazole
118. PKC412-a protein kinase inhibitor with a broad therapeutic potential
119. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumour activity
120. Phase I and pharmacokinetic study of PKC412, an inhibitor pf protein kinase C
121. Pkc 412
122. Updated Results of an exploratory Phase II study on a protein kinase C inhibitor in low-grade lymphoproliferative disorders
123. UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: A new generation of anti-cancer agents for the new century?
124. Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation
125. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor
126. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells
127. 2 checkpoint function in cancer cells with disrupted p53
128. 1 checkpoint function as determinants of resistance of human lung cancer cells against the antisignalling drug UCN-01 (7-Hydroxystaurosporine)
129. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2
130. Antitumour activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumour models
131. 2 arrest by 7-hyroxystaurosporine (UCN-01) and the impact of p53 status
132. Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumour activity
133. Surprising pharmacokinetics of UCN-01 in patients with refractory neoplasms may be due to high degree of protein binding
134. A Phase I and pharmacologic study of UCN-01, a protein kinase C inhibitor
135. Activation of protein kinase C subtypes alpha, gamma, delta, epsilon, zeta, and eta by tumour-promoting and nontumour-promoting agents
136. Chemistry and clinical biology of the bryostatins
137. The Guanine Nucleotide Exchange Factor RasGRP Is a High-Affinity Target for Diacylglycerol and Phorbol Esters
138. Beta 2-Chimaerin Is a High Affinity Receptor for the Phorbol Ester Tumour Promoters
139. Characterisation of the cysteine-rich region of the Caenorhabditis elegans protein Unc-13 as a high affinity phorbol ester receptor. Analysis of ligand-binding interactions, lipid cofactor requirements, and inhibitor sensitivity
140. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: Dissociation of activities using 26-epibryostatin 1
141. The potential for isoenzyme-selective modulation of protein kinase C
142. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumour cell lines: In vitro versus in vivo activity
143. CRC/EORTC/NCI Joint Formulation Working Party: Experiences in the formulation of investigational cytotoxic drugs
144. A Phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion
145. Phase I trial of prolonged infusion bryostatin 1 in patients with advanced cancer
146. A Phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer
147. A Phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
148. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
149. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma
150. Imidazole and Triazole Substituted Ether Phospholipids: Potent Antitumour Agents
151. Partial Inhibition of Multidrug Resistance by Safingol Is Independent of Modulation of P-glycoprotein Substrate Activities and Correlated with Inhibition of Protein Kinase C
152. Imofosine (BM41440), a new cytotoxic ether phospholipid
153. Synergistic enhancement of the antiproliferative activity of cisdiamminedichloroplatinum(II) by the ether lipid analogue BM 41440, an inhibitor of protein kinase C
154. 2 phase and suppresses CDC2 kinase activation through a mechanism different from that of DNA damaging agents
155. Effects of hexadecylphosphocholine on thrombocytopoiesis
156. D-21266, a New Heterocyclic Alkylphospholipid with Antitumour Activity
157. Phase I Study of Perifosine (D21266), a New Alkylphosphocholine Analogue
158. Phase II Study of 6% Miltefosine Solution (MILTEX®) as Local Treatment in Cutaneous Metastatic Breast Cancer (MBC) Patients
159. Preclinical activity of ilmofosine against human tumour colony forming units in vitro
160. Phase I trial of ilmofosine as a 24 hour infusion weekly
161. A Phase II trial of ilmofosine in non-small cell bronchogenic carcinoma
162. Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase
163. Protein kinase C isoforms involved in regulation of cell shape and locomotion of human fibrosarcoma HT1080 cells
164. Pharmacological inhibition of protein kinase C activity could induce apoptosis in gastric cancer cells by differential regulation of apoptosis-related genes
165. Up-regulation of p21WAF1 expression in myeloid cells is activated by the protein kinase C pathway
166. Anti-inflammatory effects of the protein kinase C inhibitor, Ro-31-8220
167. Ro-318220 inhibits dihyropyridine-sensitive isometric force and whole cell Ba2+ current in rats isolated basilar artery
168. The protein kinase C inhibitor Ro32-0432 significantly enhances mitomycin-C induced apoptosis
169. Ro 32-0432, a selective and orally active inhibitor of protein kinase C prevents T-cell activation
170. Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction
171. Characterisation of apoptosis induced by protein kinase C inhibitors and its modulation by the caspase pathway in acute promyelocytic leukaemia
172. Cell proliferation in human prostatic smooth muscle cells involves the modulation of protein kinase C isozymes
173. Inhibition of protein kinase C-alpha isoform enhances the P- glycoprotein expression and the survival of LoVo human colon adenocarcinoma cells to doxorubicin exposure
174. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signalling pathways
175. Antisense oligonucleotides as therapeutic agents
176. Intracellular mRNA cleavage induced through activation of RNase P by nuclease-resistant external guide sequences
177. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer
178. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer
179. A Phase I study of ISIS 3521, an antisense inhibitor of protein kinase C-alpha, combined with carboplatin and paclitaxel in patients with cancer
180. Clinical development of phosphorothioate antisense oligodeoxynucleotide inhibitors of PKC-alpha mRNA (ISIS 3521) and C-rafkinase (ISIS 5132)
181. Phase I/II trial of ISIS-3521, an antisense inhibitor of protein kinase C-alpha, with carboplatin and paclitaxel in non-small cell lung cancer
182. FDA grants Isis Pharmaceuticals fast track review status for ISIS-3521 in non-small cell lung cancer
183. Isis Pharmaceuticals initiates Phase II study of ISIS-3521 in non-small cell lung cancer
184. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
185. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart
186. Identification of PKC-isoform-specific biological actions using pharmacological approaches
187. Enzymatic rationale and preclinical support for a potent protein kinase C-beta inhibitor in cancer therapy
188. Protein kinase C beta1 is implicated in the regulation of neuroblastoma cell growth and proliferation
189. Anti-angiogenic and antitumour effects of a protein kinase C-beta inhibitor in human hepatocellular and gastric cancer xenografts
190. Anti-angiogenic and antitumour effects of a protein kinase C-beta. Inhibitor in human T98G glioblastoma multiforme xenografts
191. Diabetic vascular disease and the rising star of Protein Kinase C
192. Protein Kinase C activation: Isozyme-specific effects on metabolism and cardiovascular complications in diabetes
193. The therapeutic potential of targeting the cell cycle
194. The radiosensitising agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1
195. Bryostatin 1 induces biphasic activation of protein kinase D in intact cells
196. Enantioselective Synthesis and Antiproliferative Properties of an Ilmofosine Analogue, 2′-(Trimethylammonio)ethyl 3-(Hexadecyloxy)-2-(methoxymethyl)propyl Phosphate, on Epithelial Cancer Cell Growth
197. Cytotoxic activity of the thioether phospholipid analogue BM 41.440 in primary human tumour cultures
198. Go 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro
199. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976
200. Go 6976 is a potent inhibitor of neurotrophin-receptor intrinsic tyrosine kinase